NASDAQ: IBRX

ImmunityBio (IBRX) Stock Analysis & Forecast

Nov 13 close

$6.02−0.05 (−0.8%)

Gekko Brief

AI summaryNov 9 close

ImmunityBio fell 17.7% this week after third-quarter results showed product revenue up 53% year-over-year to $48.7 million, with first nine months U.S. revenue up 92% to $143.6 million, but the quarterly figure missed Wall Street's estimate and came in below the prior quarter. The company reported a loss of $0.22 per share against a $0.08 estimate, compared with a $0.07 loss a year earlier, and disclosed "substantial doubt" about its ability to continue without additional funding. Alongside the earnings, ImmunityBio announced an expanded FDA approval for ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer, and reported that the ANKTIVA plus BCG combination met the primary efficacy endpoint in the QUILT-2.005 trial for BCG-naïve non-muscle invasive bladder cancer.

Shares closed at $7.11, between the 50-day average of $8.72 and the 200-day average of $7.96, with one-month returns down 32.4% and six-month returns down 12.3%, against a one-year return of 235.4%. The GekkoIndex reads 66.7, placing the stock in the Accumulation zone, and the price sits 34.7% below the Gekko Fair Value of $10.89.

The next earnings date is 2 March 2027, 99 days away, outside a typical 20-trading-day hold. Over the last 90 days, Congress recorded 2 buys and 0 sells, and one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged -4.5% over 5 years, rising in 3 of them, a contrast worth noting against the current Accumulation reading. Analyst coverage from 4 firms is unanimously rated buy, with a consensus target of $14.25.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

ImmunityBio price vs fair value

$10.53$6.02Nov ’25May ’26Nov ’26
Close $6.02200-day averageGekko Fair Value $10.53

ImmunityBio quick facts

Market cap
$6.40B
P/E ratio
—
Forward P/E
66.7
EPS, TTM
−$1.06
Revenue, TTM
$182.6M
Profit margin
0%
Dividend yield
—
Beta
0.17
Volume
13.30M avg 13.28M
1-year return
+192.2%
Typical daily move
±11.8%
Typical 20-day move
±14.8%
50-day average
$8.59
200-day average
$7.97
Next earnings
Feb 22
Shares outstanding
1.06B
52-week range
$1.95$12.43

ImmunityBio swing-trade checklist

ImmunityBio scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $6.02 sits between the 50-day ($8.59) and 200-day ($7.97) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    70.9, Buying

    Reading 70.9 is in the Buying zone.

    See the GekkoIndex
  • Fair valuesupportive

    42.8% below

    Price is 42.8% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: Congress 2 buys / 0 sales.

    See smart money
  • Earnings risksupportive

    Reports in 99 days

    Next report Feb 22, 2027, 99 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    −6.9% on average

    From this point in the calendar, the next 20 trading days averaged −6.9% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

ImmunityBio stock chart and price history

ImmunityBio closed at $6.02 on Nov 13, 2026, +192.2% over the past year, inside a 52-week range of $1.95 to $12.43.

Close50-day average200-day averageVolume
ImmunityBio share price, past year, with 50-day and 200-day moving averages and volume$2$4$8$10$12DecJan 2026FebMarAprMayJunJulAugSepOctNov6.02

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−39.8%
3 months
−24.0%
6 months
−24.5%
1 year
+192.2%
The full IBRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IBRX in Gekko

Follow ImmunityBio through every session

Put IBRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track IBRX in GekkoFree for 7 days. No credit card required.

About ImmunityBio

ImmunityBio works on medicines still in clinical testing, aimed at cancer and infectious disease. It builds its work around a range of immune-based approaches, including antibody-cytokine fusion proteins, engineered immunomodulators, vaccine technologies, natural killer cell therapies, and methods that engage the body's T-cell response. Several of its treatment candidates have reached Phase II or III trials, targeting tumors such as bladder, pancreatic, and lung cancer, along with pathogens like SARS-CoV-2 and HIV.

The company pursues its research partly through outside collaboration, working with organizations such as the National Cancer Institute and the National Institute of Deafness and Communication Disorders, as well as Amyris. It also holds licensing agreements with a number of firms, among them CytRx, EnGeneIC, GlobeImmune, the Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology, Sorrento Therapeutics, and Viracta Therapeutics, reflecting a network of shared research and technology arrangements rather than a single in-house pipeline.

ImmunityBio was founded in 2014 and is based in San Diego, California. Its shares are listed on the NASDAQ under the ticker IBRX.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
immunitybio.com

ImmunityBio GekkoIndex: the smart money zone

ImmunityBio’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 70.9, in the Buying zone, up 11.4 points over five sessions.

010070.9Buying

Up 11.4 points over five sessions, from the Neutral zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying (current zone)44+2.7%+6.2%+10.2%+20.5%
Accumulation262+2.8%+6.4%+14.5%+33.3%
Neutral352+0.8%+2.0%+1.3%+8.2%
Distribution37+3.3%−1.4%+4.5%+0.3%
Selling7Too few readings yet

Average IBRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.

Buying zone: Smart money likely accumulating heavily. About the five zones →

See every daily GekkoIndex reading plotted over the IBRX price, zone by zone.Track IBRX in Gekko

Is ImmunityBio stock overvalued? Gekko Fair Value

ImmunityBio trades 42.8% below Gekko Fair Value of $10.53, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what ImmunityBio shares are worth, recalculated every trading day.

$10.53

Gekko Fair Value, Nov 14, 2026

42.8% Undervalued

At the end of Aug 2026 the price was 28.0% below the estimate.

Gekko Fair ValueShare price, month end
$11$6Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open IBRX in Gekko

ImmunityBio insider and Congress trading

No open-market insider purchases were filed for ImmunityBio, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for IBRX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every IBRX insider filing, plotted on the chart in Gekko.Open IBRX in Gekko

Congress trades last 90 days

2trades disclosed: 2 purchases and 0 sales.

MemberTypeAmountDisclosed
Lisa McClain
House, MI, purchase
Purchase$1,001 - $15,000Oct 12
traded Sep 30
Lisa McClain
House, MI, purchase
Purchase$1,001 - $15,000Oct 12
traded Sep 28

From congressional disclosures, which report amounts as ranges.

Buybacks

ImmunityBio has been buying back its own shares.

Bought back, quarter ended Sep 30, 2023
$1.46M
As a share of market cap
0.02%

From company filings.

Hedge funds and billionaires quarter ended Sep 30

0of the funds Gekko tracks hold IBRX.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

ImmunityBio earnings: next date and track record

ImmunityBio reports on Feb 22, 2027 (99 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±10.4%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−11.4%Nov ’24−8.2%Mar ’25+21.3%May ’25−1.2%Aug ’25−4.9%Nov ’25+32.8%Feb ’26+1.6%May ’26+1.4%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 4, 2026−$0.22
est −$0.08
−175.0%$51.24M
est $49.70M
+3.1%+1.4%
May 7, 2026−$0.08
est −$0.07
−14.3%$44.21M
est $43.07M
+2.6%+1.6%
Feb 23, 2026−$0.06
est −$0.11
+45.8%$38.29M
est $38.36M
−0.2%+32.8%
Nov 4, 2025−$0.07
est −$0.10
+30.0%$32.06M
est $37.78M
−15.1%−4.9%
Aug 5, 2025−$0.10
est −$0.10
0.0%$26.43M
est $31.88M
−17.1%−1.2%
May 12, 2025−$0.15
est −$0.16
+6.3%$16.52M
est $16.60M
−0.5%+21.3%
Mar 3, 2025−$0.08
est −$0.13
+38.5%$7.55M
est $9.63M
−21.5%−8.2%
Nov 12, 2024−$0.12
est −$0.18
+33.3%$6.11M
est $9.07M
−32.7%−11.4%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

ImmunityBio stock forecast and analyst price targets

Analysts’ average 12-month price target for ImmunityBio is $14.25, +136.7% from the last close, from 4 firms rating the stock in the last 90 days.

$14.25consensus 12-month target, +136.7% from the last close
Low $12High $16
Buy4
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 4 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9H.C. WainwrightBuy, maintained$15+149.2%
Nov 9BTIGBuy, maintained$12+99.3%
Oct 29BTIGBuy, maintained$12+99.3%
Oct 15H.C. WainwrightBuy, reiterated$15+149.2%
Oct 14Piper SandlerBuy, maintained$16+165.8%
+10.2%average 20-day move after past Buying readings
−6.9%average move over the next 20 trading days in the last 5 years
±11.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

ImmunityBio seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, ImmunityBio averaged −6.9% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−20.6%2021+8.3%2022+8.3%2023−41.1%2024+6.7%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−5.3%2 of 5
Next 10 trading days+4.0%4 of 5
Next 15 trading days−3.5%2 of 5
Next 20 trading days−6.9%3 of 5
Next 30 trading days−8.2%1 of 5

For scale, IBRX’s typical 20-trading-day move in either direction is about 14.8%.

ImmunityBio market cap and key statistics

ImmunityBio’s market cap is $6.40B and revenue of $182.6M over the last twelve months.

Valuation

Market cap
$6.40B
Forward P/E
66.7
EPS, TTM
−$1.06
Gekko Fair Value
$10.53

Trading

Volume
13.30M
Avg volume, 20 days
13.28M
52-week high
$12.43
52-week low
$1.95
Shares outstanding
1.06B

Financials

Revenue, TTM
$182.6M
Profit margin
0%
Return on equity
0%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.17
Typical daily move
±11.8%
Typical 20-day move
±14.8%

ImmunityBio peers

ImmunityBio’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

ImmunityBio stock FAQ

What is ImmunityBio’s market cap?

ImmunityBio’s market cap is $6.40B at the Nov 13, 2026 close of $6.02, with 1.06B shares outstanding.

What is the ImmunityBio stock forecast?

The consensus analyst 12-month price target for ImmunityBio is $14.25, +136.7% from the last close. Of the 4 firms that rated the stock in the last 90 days, 4 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is ImmunityBio stock overvalued or undervalued?

On Gekko’s estimate ImmunityBio is undervalued: the Nov 13, 2026 close of $6.02 is 42.8% below Gekko Fair Value of $10.53. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does ImmunityBio report earnings next?

ImmunityBio is expected to report on Feb 22, 2027 (99 days away). Analysts expect earnings of −$0.14 per share on revenue of $56.73M. ImmunityBio beat the earnings estimate in 5 of its last 8 reports, moving 10.4% on average across the report.

What is ImmunityBio’s 52-week high and low?

ImmunityBio’s 52-week high is $12.43 and its 52-week low is $1.95; it closed at $6.02 on Nov 13, 2026, +192.2% over the past year.

Is ImmunityBio stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See ImmunityBio the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.